High-Dose Interleukin-2 (HD IL-2) Therapy Should Be Considered for Treatment of Patients with Melanoma Brain Metastases. (12th May 2013)

• Record Type: Journal Article
• Authors: Chu, Melinda B.; Fesler, Mark J.; Armbrecht, Eric S.; Fosko, Scott W.; Hsueh, Eddy; Richart, John M.
• Other Names: Georgoulias Vassilios A. Academic Editor.
• Is Part Of: Chemotherapy research and practice. Volume 2013(2013)
• Publication Date: 2013-05-12
• Subjects: Chemotherapy -- Periodicals; Drug Therapy; Pharmaceutical Preparations; Chemotherapy; Electronic journals; Periodical; Periodicals; Fulltext; Internet Resources; Periodicals; 615.58
• DOI: 10.1155/2013/726925
• Languages: English
• ISSNs: 2090-2107

Abstract

Abstract : A retrospective review was performed on patients with stable melanoma brain metastases treated with HD IL-2 therapy (720, 000 IU/kg per dose intravenously; 14 doses, 2 cycles per course, maximum 2 courses) from January 1999 to June 2011 at Saint Louis University. There were 5 men and 3 women; median age was 52.2 years (26.8–61.1 years). One patient started treatment with lung lesions only (after resection of melanoma brain disease) and experienced partial response. Seven patients had brain metastases at treatment initiation. Median overall survival (mOS) for entire cohort (n = 8 ) was 8.7 months (2.1 to 19.0 months). All patients with brain metastases at first dose (n = 7 ) showed progressive disease; mOS was 6.7 months (range 2.1–18.2 months) for this group. Patients received radiosurgery and whole brain radiation before and after HD IL-2 therapy. One patient had symptoms suggestive of neurotoxicity. A history of alcohol abuse was revealed during admission. The patient's symptoms improved with initiation of an alcohol withdrawal protocol. In this analysis, patients with melanoma brain metastases received HD IL-2 without treatment-related mortality. We think that HD IL-2 should be considered as a treatment option in patients with melanoma brain metastases who are otherwise eligible for therapy.